Evidence map›Paper›PMID 39867069›Full record

ArticleCureus2024

Association Between HbA1c Levels and the Severity of Diabetic Retinopathy.

Nayef Alswaina

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nayef AlswainaDepartment of Ophthalmology, College of Medicine, Qassim University, Kingdom of Saudi Arabia, Buraidah, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic retinopathy (DR) is a significant microvascular complication of diabetes mellitus (DM), contributing to visual impairment and blindness worldwide. Understanding the factors associated with the severity of DR is crucial for effective prevention and management. This study aimed to explore the association between hemoglobin A1c (HbA1c) level and other parameters with different stages of DR. METHODOLOGY: A retrospective cross-sectional study was conducted on patients diagnosed with DR between March and September 2024. Patients with type 2 diabetes who underwent fundus examinations and had HbA1c measurements were analyzed. Data on demographic and clinical parameters, including age, gender, duration of diabetes, glycemic control, anti-diabetic medications, body mass index (BMI), and diabetes-related complications, were collected. The severity of DR was classified into mild, moderate, and severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). Statistical analyses included chi-square tests, independent t-tests, and analysis of variance (ANOVA), with

resultsA total of 106 participants were included, with a mean age of 57.3 years. PDR was present in 27 patients (25.5%), while 43 patients (40.6%) had mild NPDR. Very poor glycemic control (HbA1c > 9%) was noted in 36 patients (34%). Insulin use was significantly associated with higher DR severity (

conclusionsThe study highlights that uncontrolled glycemic level, longer diabetes duration, and the presence of macular edema are key factors associated with the severity of DR. Insulin use may indicate a higher risk of severe DR, emphasizing the need for comprehensive diabetes management and regular ophthalmologic evaluations. These findings underscore the importance of targeted interventions to prevent vision-threatening complications in diabetic patients.

Indexed as

diabetes complicationsdiabetic retinopathyglycemic controlsaudi arabiatype 2 diabetes

Identifiers

PMID39867069
PMCPMC11762433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.